Assembly Biosciences(ASMB) - 2023 Q4 - Annual Results

Exhibit 99.1 Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights • Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end • Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of Phase 1b in individuals with recurrent genital herpes by end of 2024 and interim Phase 1b data available in 1H2025 • Gilead Sciences, In ...